NCT04521621: A reported trial by Merck Sharp & Dohme LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04521621 |
|---|---|
| Title | A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 28, 2020 |
| Completion date | July 25, 2023 |
| Required reporting date | July 24, 2024, midnight |
| Actual reporting date | July 12, 2024 |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |